Currently out of the existing stock ratings of Mason Carrico, 47 are a BUY (92.16%), 4 are a HOLD (7.84%).

Mason Carrico

Work Performance Price Targets & Ratings Chart

Analyst Mason Carrico, currently employed at STEPHENS, carries an average stock price target met ratio of 34.52% that have a potential upside of 16.37% achieved within 122 days.

Mason Carrico’s has documented 102 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CDNA, Caredx at 27-Feb-2025.

Wall Street Analyst Mason Carrico

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 5/24/2022. The price target of $25 was fulfilled within 16 days with a profit of $5.31 (26.97%) receiving and performance score of 16.86.

Average potential price target upside

of $11.82 (19.74%) on NTRA (NATERA).
of $9.93 (47.03%) on VCYT (VERACYTE).
of $3.72 (27.97%) on NEO (NEOGENOMICS).

CSTL Castle Biosciences DMTK DermTech GH Guardant Health OCX OncoCyte Corp VCYT Veracyte AKYA Akoya Biosciences MYGN Myriad Genetics CDNA Caredx NEO NeoGenomics TXG 10X Genomics ILMN Illumina NTRA Natera PACB Pacific Biosciences of California HOLX Hologic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Mason Carrico (STEPHENS)